» Articles » PMID: 15542809

Prognostic Factors in Resected Stage I Non-small-cell Lung Cancer: a Multivariate Analysis of Six Molecular Markers

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2004 Nov 16
PMID 15542809
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To analyze the prognostic significance of six molecular biomarkers (death-associated protein kinase [DAPK] promoter methylation, interleukin-10 [IL-10] protein expression, cyclooxygenase-2 [COX-2] mRNA expression, human telomerase reverse transcriptase catalytic subunit [hTERT] mRNA expression, retinoic acid receptor-beta [RAR-beta] mRNA expression, and K-ras mutational status) in stage I non-small-cell lung cancer (NSCLC) patients.

Patients And Methods: Biomarker analyses were performed on tumors from 94 patients with stage I NSCLC who underwent surgical resection at our institution. A minimum follow-up period of 5 years was required. DAPK methylation was assessed by methylation-specific polymerase chain reaction (PCR). RAR-beta, COX-2, and hTERT mRNA levels were determined by in situ hybridization with digoxigenin-labeled antisense riboprobes. K-ras mutation status was determined by the PCR-primer introduced restriction with enrichment for mutant alleles method. IL-10 protein expression was analyzed by immunohistochemistry using a polyclonal antihuman IL-10 antibody. Cancer-specific survival was analyzed with a Cox proportional hazards model. To identify independent prognostic factors, a stepwise selection method was used.

Results: DAPK methylation, IL-10 lack of expression, COX-2 expression, hTERT expression, RAR-beta expression, and K-ras mutations were observed in 46.8%, 29.8%, 59.6%, 34.0%, 23.4%, and 34.0% of patients, respectively. In the final model, DAPK methylation and IL-10 lack of expression were significant negative prognostic factors for cancer-specific survival, whereas COX-2 expression was of borderline significance.

Conclusion: In this cohort of resected stage I NSCLC patients, molecular markers that independently predict cancer-specific survival have been identified. The prognostic roles of DAPK methylation, IL-10, and other biomarkers in NSCLC merit further investigation.

Citing Articles

Therapeutic and Phytochemical Properties of Thymoquinone Derived from .

Tiwari G, Gupta M, Devhare L, Tiwari R Curr Drug Res Rev. 2023; 16(2):145-156.

PMID: 37605475 DOI: 10.2174/2589977515666230811092410.


Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review.

Gallina F, Bertolaccini L, Forcella D, Mohamed S, Ceddia S, Melis E Cancers (Basel). 2022; 14(8).

PMID: 35454856 PMC: 9024905. DOI: 10.3390/cancers14081949.


Loss of death-associated protein kinase 1 in human bone marrow mesenchymal stem cells decreases immunosuppression of CD4+ T cells.

Wang S, Su H, Feng P, Deng W, Su C, Wu Y J Int Med Res. 2020; 48(6):300060520933453.

PMID: 32586165 PMC: 7323303. DOI: 10.1177/0300060520933453.


Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies.

Nunes S, Diniz F, Moreira-Barbosa C, Constancio V, Silva A, Oliveira J J Clin Med. 2019; 8(9).

PMID: 31546933 PMC: 6780554. DOI: 10.3390/jcm8091500.


Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis.

Zhang Y, Wu J, Huang G, Xu S Cancer Manag Res. 2018; 10:6897-6904.

PMID: 30588095 PMC: 6296685. DOI: 10.2147/CMAR.S174815.